Kamada Ltd KMDA
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $53.65M, -19.7% YoY · Filed Mar 11, 2026
Kamada Ltd (KMDA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $53.6 million and net income of $20.2 million. As of Dec 31, 2025 it held $75.5 million in cash and investments and $21.5 million in total debt.
Revenue
$53.65M
-19.7% vs prior year
Net income
$20.20M
+39.7% vs prior year
Operating cash flow
$25.49M
-46.4% vs prior year
Free cash flow
—
EPS
$0.35
+40.0% vs prior year
Dividend per share
None
Shares outstanding
57.69M
+0.3% vs prior year
Net cash
$53.98M
FY 2025
Operating margin
48.9%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KMDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Rehovot, Israel
- SEC filer status
- Accelerated filer
- SEC CIK
- 1567529
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $53.6M | $66.8M | $48.9M | $129.3M | $103.6M |
| Operating income | $26.2M | $20.1M | $10.1M | $4.5M | -$696,000 |
| Net income | $20.2M | $14.5M | $8.3M | -$2.3M | -$2.2M |
| Diluted EPS | $0.35 | $0.25 | $0.15 | -$0.05 | -$0.05 |
| Operating cash flow | $25.5M | $47.6M | $4.3M | $28.6M | -$8.8M |
| Total assets | $378.7M | $372.3M | $354.9M | $322.4M | $318.7M |
| Stockholders' equity | $269.1M | $259.5M | $244.0M | $176.0M | $176.8M |
| Cash and investments | $75.5M | $78.4M | $55.6M | $34.3M | $18.6M |
| Total debt | $21.5M | $21.2M | $7.4M | $28.5M | $6.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 2, 2026 | Nov 2, 2026 |
| 6-K | Current report (foreign issuer) | Oct 6, 2026 | Oct 6, 2026 |
| 6-K | Current report (foreign issuer) | Oct 5, 2026 | Oct 5, 2026 |
| 6-K | Current report (foreign issuer) | Sep 17, 2026 | Sep 17, 2026 |
| 6-K | Current report (foreign issuer) | Sep 10, 2026 | Sep 10, 2026 |
| 6-K | Current report (foreign issuer) | Sep 3, 2026 | Sep 3, 2026 |
All 538 Kamada Ltd SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.